Micrima is developing radiowave radar technology for medical imaging applications.
Our primary interest is in breast cancer where we intend to provide the first truly alternative screening modality for decades.
With its inherent advantages over existing modalities, Micrima’s patented techniques will enable breast screening to become safer, more convenient, more accessible, more desired by the female population and more economically viable in an increased number of countries, and locations within those countries.
The technology is non-invasive, non-ionising and inexpensive. It has
benefited from extensive validation in the laboratory and is now undergoing clinical trials.